Medical Cannabis vs. Synthetic Cannabinoids: What Does the Future Hold?

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 6, 2015, Pages 568-570

  Bolognini, D ^a,b   Ross, R A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; CANNABINOID RECEPTOR; MEDICAL CANNABIS; NABIXIMOLS; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

CANCER PAIN; CHRONIC PAIN; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; GLUCOSE HOMEOSTASIS; HUMAN; LIPOGENESIS; MUSCLE SPASM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; MEDICINAL CHEMISTRY; PHYSIOLOGY; SYNTHESIS;

CANNABINOIDS; CHEMISTRY, PHARMACEUTICAL; HUMANS; MEDICAL MARIJUANA; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84938915109     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.107     Document Type: Review

References (5)

1. Pertwee, R.G. Handbook of Cannabis, 1st ed. (Oxford University Press, Oxford, 2014).
2. Dhopeshwarkar, A. & Mackie, K. CB2 cannabinoid receptors as a therapeutic target-what does the future hold? Mol. Pharmacol. 86, 430-437 (2014).
3. Chorvat, R.J. Peripherally restricted CB1 receptor blockers. Bioorg. Med. Chem. Lett. 23, 4751-4760 (2013).
4. Tepper, M.A., Zurier, R.B. & Burstein, S.H. Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg. Med. Chem. 22, 3245-3251 (2014).
5. Vallee, M., et al. Pregnenolone can protect the brain from cannabis intoxication. Science 343, 94-98 (2014).